Table 2 Mean time to cancer identification and primary site of malignancy among ESKD patients.
Cancer sites | Event, n (%) | Time to identification of cancer, years, mean (SD) | PY | IR per 10,000 | 95% CI | Specific sites | Event, n (%) |
|---|---|---|---|---|---|---|---|
All sites | 3292 (5.6) | 3.29 (1.90) | 197,199 | 166.9 | 161.2–172.6 | – | – |
Digestive tract | 1380 (41.9) | 3.23 (1.91) | 200,284 | 68.9 | 65.3–72.5 | Stomach | 333 (24.1) |
Colorectal | 436 (31.6) | ||||||
Liver | 348 (25.2) | ||||||
Pancreaticobiliary | 221 (16.0) | ||||||
Other GI tract | 42 (3.1) | ||||||
Urinary tract | 367 (11.2) | 3.46 (1.91) | 201,766 | 18.2 | 16.3–20.1 | Kidney | 227 (61.9) |
Bladder | 115 (31.3) | ||||||
Ureter | 24 (6.5) | ||||||
Urethra and other | 1 (0.3) | ||||||
Respiratory tract | 427 (13.0) | 3.15 (1.77) | 202,070 | 21.1 | 19.1–23.1 | Lung | 417 (97.7) |
Larynx, Trachea | 10 (2.3) | ||||||
Reproductive | 283 (8.6) | 3.45 (1.91) | 201,965 | 14.0 | 12.4–15.6 | Cervix | 57 (20.1) |
Uterine | 21 (7.4) | ||||||
Ovary | 31 (11.0) | ||||||
Prostate | 160 (56.5) | ||||||
Others | 14 (5.0) | ||||||
Head and neck | 96 (2.9) | 3.44 (1.95) | 202,358 | 4.7 | 3.8–5.7 | Oral cavity, lip, pharynx | 55 (57.3) |
Others | 41 (42.7) | ||||||
Hematologic | 134 (4.1) | 3.15 (1.85) | 202,298 | 6.6 | 55.0–77.5 | Multiple myeloma | 52 (38.8) |
Lymphoma | 44 (32.8) | ||||||
Others | 38 (28.4) | ||||||
Endocrine | 154 (4.7) | 3.57 (2.12) | 202,124 | 7.6 | 6.4–8.8 | Thyroid | 144 (93.5) |
Others | 10 (6.5) | ||||||
Other organs | 451 (13.7) | 3.30 (1.88) | 201,675 | 22.4 | 20.3–24.4 | Breast | 133 (29.5) |
Skin | 167 (37.0) | ||||||
Others | 151 (33.5) |
